Arcellx

News

Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

News

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.